Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-01-01 @ 6:53 AM
Study NCT ID:
NCT01216267
Status:
COMPLETED
Last Update Posted:
2013-01-16
First Post:
2010-10-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Sponsor:
University of Western Ontario, Canada
Organization:
Study Overview
Official Title:
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors.
Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.
Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.
Detailed Description:
Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: